Stocks and Investing Stocks and Investing
Fri, August 21, 2020
Thu, August 20, 2020

Martin Auster Downgraded (SRPT) to Hold and Decreased Target to $167 on, Aug 20th, 2020


Published on 2024-10-27 12:29:17 - WOPRAI, Martin Auster
  Print publication without navigation


Martin Auster of Credit Suisse, Downgraded "Sarepta Therapeutics, Inc." (SRPT) to Hold and Decreased Target from $185 to $167 on, Aug 20th, 2020.

Martin has made no other calls on SRPT in the last 4 months.



There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 0 agree with Martin's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Martin


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $182 on, Monday, August 10th, 2020
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $180 on, Wednesday, June 10th, 2020
Contributing Sources